Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Primary Biliary Cirrhosis Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.4% during the forecast period.
This report presents the market size and development trends by detailing the Primary Biliary Cirrhosis Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Primary Biliary Cirrhosis Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Primary Biliary Cirrhosis Drug industry and will help you to build a panoramic view of the industrial development.
Primary Biliary Cirrhosis Drug Market, By Type:
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
Primary Biliary Cirrhosis Drug Market, By Application:
Clinic
Hospital
Others
Some of the leading players are as follows:
GlaxoSmithKline Plc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc
Virobay Inc
Dr Falk Pharma GmbH
Intercept Pharmaceuticals, Inc
CymaBay Therapeutics, Inc.
AlbireoPharma.
Johnson & Johnson.
NGM Biopharmaceuticals, Inc.
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Primary Biliary Cirrhosis Drug Market: Technology Type Analysis
-
4.1 Primary Biliary Cirrhosis Drug Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Primary Biliary Cirrhosis Drug Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Budesonide
4.3.2 FFP-104
4.3.3 GSK-2330672
4.3.4 MBX-8025
4.3.5 NGM-282
4.3.6 Others
5 Primary Biliary Cirrhosis Drug Market: Product Analysis
-
5.1 Primary Biliary Cirrhosis Drug Product Market Share Analysis, 2018 & 2026
-
5.2 Primary Biliary Cirrhosis Drug Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Primary Biliary Cirrhosis Drug Market: Application Analysis
-
6.1 Primary Biliary Cirrhosis Drug Application Market Share Analysis, 2018 & 2026
-
6.2 Primary Biliary Cirrhosis Drug Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
7 Primary Biliary Cirrhosis Drug Market: Regional Analysis
-
7.1 Primary Biliary Cirrhosis Drug Regional Market Share Analysis, 2018 & 2026
-
7.2 Primary Biliary Cirrhosis Drug Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 GlaxoSmithKline Plc.
9.1.1 GlaxoSmithKline Plc. Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Dr. Falk Pharma GmbH
9.2.1 Dr. Falk Pharma GmbH Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Enanta Pharmaceuticals, Inc
9.3.1 Enanta Pharmaceuticals, Inc Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Virobay Inc
9.4.1 Virobay Inc Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Dr Falk Pharma GmbH
9.5.1 Dr Falk Pharma GmbH Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Intercept Pharmaceuticals, Inc
9.6.1 Intercept Pharmaceuticals, Inc Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 CymaBay Therapeutics, Inc.
9.7.1 CymaBay Therapeutics, Inc. Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 AlbireoPharma.
9.8.1 AlbireoPharma. Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Johnson & Johnson.
9.9.1 Johnson & Johnson. Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 NGM Biopharmaceuticals, Inc.
9.10.1 NGM Biopharmaceuticals, Inc. Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
The List of Tables and Figures (Totals 110 Figures and 149 Tables)
Figure Budesonide Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure FFP-104 Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure GSK-2330672 Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure MBX-8025 Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure NGM-282 Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure Others Primary Biliary Cirrhosis Drug market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Primary Biliary Cirrhosis Drug market, by country, 2015 - 2026 (USD Million)
-
Table North America Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table North America Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table North America Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Canada Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Canada Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Europe Primary Biliary Cirrhosis Drug market, by country, 2015 - 2026 (USD Million)
-
Table Europe Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Europe Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Europe Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Germany Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Germany Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table France Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table France Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Italy Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Italy Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Spain Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Spain Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Primary Biliary Cirrhosis Drug market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table China Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table China Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Japan Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Japan Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table India Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table India Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Primary Biliary Cirrhosis Drug market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table MEA Primary Biliary Cirrhosis Drug market, by country, 2015 - 2026 (USD Million)
-
Table MEA Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table MEA Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table MEA Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Primary Biliary Cirrhosis Drug market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Primary Biliary Cirrhosis Drug market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Primary Biliary Cirrhosis Drug market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table GlaxoSmithKline Plc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr. Falk Pharma GmbH Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Enanta Pharmaceuticals, Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Virobay Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Dr Falk Pharma GmbH Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Intercept Pharmaceuticals, Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table CymaBay Therapeutics, Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AlbireoPharma. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table NGM Biopharmaceuticals, Inc. Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
